SLGL
Sol-Gel Technologies Ltd.NASDAQHealthcare$74.34-6.44%ClosedMarket Cap: $208.9M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
9.08
P/S
10.77
EV/EBITDA
18.26
DCF Value
$-59.71
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-39.2%
Net Margin
-31.6%
ROE
-24.3%
ROA
-20.5%
ROIC
-31.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $696.0K | 84.3% | $-21.6M | $-3.0M | $-1.07 | — |
| FY 2025 | $19.4M | 99.4% | $-7.6M | $-6.1M | $-2.20 | — |
| Q3 2025 | $400.0K | 100.0% | $-6.3M | $-5.9M | $-2.13 | — |
| Q2 2025 | $17.3M | 100.0% | $11.2M | $11.6M | $4.17 | — |
| Q1 2025 | $1.0M | 100.0% | $9.1M | $-8.8M | $-0.32 | — |
| Q4 2024 | $278.0K | 100.0% | $-6.1M | $-5.8M | $-0.21 | — |
| FY 2024 | $11.5M | 98.0% | $-12.0M | $-10.6M | $-0.38 | — |
| Q3 2024 | $5.4M | 100.0% | $-828.0K | $-366.0K | $-0.01 | — |
| Q2 2024 | $5.4M | 55.1% | $1.6M | $2.0M | $0.07 | — |
| Q1 2024 | $466.0K | -1047.0% | $-6.7M | $-6.3M | $-0.23 | — |
| Q4 2023 | $447.0K | -833.1% | $-5.4M | $-4.8M | $-0.17 | — |
| FY 2023 | $1.6M | -1414.9% | $-29.3M | $-27.2M | $-1.01 | — |